SlideShare a Scribd company logo
1 of 18
Download to read offline
3Q10 Earnings Release
      November, 09th, 2010.
3Q10 Earnings Release



Highlights For The Period

• A growth of 11.8% in the consolidated gross revenues quarter-over-quarter, totaling R$ 809.8 million, highlighting
the health and beauty category, in which a sharp growth of 34.3% was recorded;

• The operating cash flow was positive for the second consecutive quarter and amounted to R$ 62.1 million in 3Q10,
or 9.1% of the net operating revenue;

• Deep drop of 17.4 days in the Company's cash cycle, which stood at 48.8 days, the shortest since 2006. This
decrease derived in a fall of about R$ 106.1 million in working capital;

• Net debt fell by 42.9% (R$ 57.4 million) quarter-over-quarter. Thus, the Company's net debt / EBITDA ratio dropped
from 1.4x (June 2010) to 0.8x;

• A 9.6% drop over 2Q10 in operating expenses (administrative, selling and logistics), which resulted in 7.1% of net
revenues, the latter figure being the second best result for the Company in two years;

• An EPM (errors per million units delivered) reduction of 23.1% from 121.0 in 2Q10 to 93.0 in 3Q10.




                                                                                                                       2
3Q10 Earnings Release




                                Gross Revenues Evolution
                                        (R$ million)




                        808.2                              809.8

                                          724.7




                        3Q09              2Q10             3Q10




                                                                   3
3Q10 Earnings Release




                                       Gross Revenues Breakdown

              (R$ Million)                     3Q10    3Q09    Chg. %   2Q10    Chg. %

              Branded                          537.8   548.5    -1.9%   477.5   12.6%
              Generic                           56.2    43.7   28.6%     50.3   11.8%
              OTC                              153.7   157.5    -2.4%   143.8    6.9%
               Health and Beauty Products       38.6    27.1   42.7%     28.8   34.3%
              Hospitals and Vaccines            23.5    31.5   -25.4%    24.3   -3.3%

              Total                            809.8   808.2    0.2%    724.7   11.8%




                                                                                         4
3Q10 Earnings Release




                                             Market Share Evolution (%)



                                                 11.7
                                      11.5
                                                             10.9*        11.0*
                                                                                         10.2*
           9.6                 9.6                                                9.5*




          2005                2006    2007       2008        2009         3Q09    2Q10   3Q10

    *Excluding the similar’s effect
                                                                                          Source: IMS




                                                                                                        5
3Q10 Earnings Release




                   Gross Profit and Revenues from Services to Suppliers
                                       (R$ million and as % Net Revenues)




                                                    12.3%
                        11.1%
                                                                                  10.2%



                         10.3
                                                     25.1
                                                                                   26.8

                         65.8

                                                     49.7                          43.3




                        3Q09                         2Q10                         3Q10
                  Gross Profit   Revenues from Services to Suppliers        Gross Profit Margin (%)




                                                                                                      6
3Q10 Earnings Release




                                  Operating Expenses
                               (R$ million and as % Net Revenues )



                                             8.9%

                        6.9%                                         7.1%


                                             53.8
                                                                     48.6
                        47.4




                        3Q09                 2Q10                    3Q10




                                                                            7
3Q10 Earnings Release




                               Net Financial Expenses
                               (R$ million and as % Net Revenues)




                                            1.9%
                        0.7%                                        0.8%

                                             11.8




                                                                    5.4
                        5.1




                        3Q09                2Q10                    3Q10




                                                                           8
3Q10 Earnings Release




                                         Net Profit
                               (R$ million and as % Net Revenues)




                        1.9%                 1.9%
                                                                    0.7%


                        13.1
                                             11.4

                                                                    4.7




                        3Q09                2Q10                    3Q10




                                                                           9
3Q10 Earnings Release




                               Ebitda and Ebitda Margin
                               (R$ million and as % Net Revenues)




                        4.1%
                                            3.6%
                                                                    3.1%

                        27.7

                                             21.8                   21.5




                    3Q09                    2Q10                    3Q10




                                                                           10
3Q10 Earnings Release




                                                         CASH FLOW
  (R$ Million)                                                       3Q10     3Q09     Chg. %     2Q10      Chg. %

  Cash Flow Generated / (Used) in Operating Activities               62.1     36.5      70.2%      46.8     32.8%
    Internal Cash Generation                                          9.5     24.1     -60.7%      17.6     -46.1%
    Operating Assets Variation                                       52.7     12.4     325.9%      29.2      80.3%
        Trade Accounts Receivable                                    (50.8)   (1.9)    -2561.4%    28.3       -
        Inventories                                                                        -                  -
                                                                     (10.2)   26.7                  92.4
        Suppliers                                                    120.7    (3.9)       -       (105.2)     -
        Other Items                                                  (7.1)    (8.5)     16.4%      13.7       -

  Cash Flow (Used) in Investing Activities                           (1.5)    (2.2)     31.9%      (1.9)    20.1%

  Cash Flow Generated / (Used) by Financing Activities               (43.8)   (17.1)   -155.9%    (53.7)    18.5%

  Net Increase / (Decrease) in Cash                                  16.9     17.2      -2.0%      (8.8)      -




                                                                                                                     11
3Q10 Earnings Release




                                      3Q06     4Q06     1Q07    2Q07     3Q07       4Q07   1Q08    2Q08     3Q08    4Q08    1Q09   2Q09   3Q09   4Q09   1Q10   2Q10 3Q10

       Cash Cycle – Days *             49.3     53.4    62.5     69.6    67.8       64.3   68.8     67.2    61.8     65.8   67.9   58.7   51.6   52.7   64.9   66.3   48.8

  Accounts Receivable (1)              45.2     50.0    54.6     53.1    50.9       51.7   50.7     49.2    47.0     45.9   42.4   40.5   38.4   41.1   43.4   42.2   43.3

  Inventories (2)                      33.1     44.7    43.4     47.2    41.3       48.6   47.9     45.7    42.5     49.9   61.6   52.4   43.7   53.9   59.9   48.8   43.9

  Accounts Payable (3)                 29.0     41.3    35.6     30.7    24.5       36.0   29.8     27.7    27.7     29.9   36.1   34.3   30.5   42.3   38.4   24.8   38.4

 * Average
(1) Average of Gross Revenues in the Quarter   (2) Average of COGS in the Quarter   (3) Average of COGS in the Quarter




                                                                                                                                                                             12
3Q10 Earnings Release




                                  Indebtedness: Net Debt and Net Debt / Ebitda*
                                                    (R$ million)



                                                      1.4x
                                0.9x                                       0.8x


                                                      132.5



                                95.0

                                                                           75.1




                               3Q09                   2Q10                 3Q10

            * Ebitda = Accumulated last 12 months




                                                                                  13
3Q10 Earnings Release



                                            Capex
                               (R$ million and as % Net Revenues)




                        0.3%                 0.3%                   0.2%


                        2.2

                                              1.9

                                                                    1.5




                    3Q09                     2Q10                   3Q10




                                                                           14
3Q10 Earnings Release



                                                    Operating Indicators

                     Service Level                                          Logistics E.P.M.
             (units served / units requested)                               (Errors per Million)



     94.1%
                                                                    120.0       121.0


                                                90.4%                                              93.0
                         89.6%




     3Q09                 2Q10                  3Q10                 3Q09       2Q10               3Q10




                                                                                                          15
3Q10 Earnings Release



                                Profarma vs Ibovespa - % 1 year



    150




    125


                                                                                             113

    100                                                                                      103




     75




     50
     30-sep-09   30-nov-09   30-jan-10        30-mar-10         30-may-10   30-jul-10   30-sep-10




                                         Ibovespa         Profarma




                                                                                                    16
3Q10 Earnings Release

                              Analyst Coverage

             Firm                     Analyst
                                      Javier Martinez de Olcoz Cerdan – Clarissa Berman
                                      Phone: (1 212) 761-4542 / (55 11) 3048-6214
             Morgan Stanley
                                      E-mail: javier.martinez.olcoz@morganstanley.com
                                      E-mail: clarissa.berman@morganstanley.com


                                      Alexandre Pizano
             Merrill Lynch            Phone: (55 11) 2188-4024
                                      E-mail: alexandre.pizano@baml.com


                                      Marcel Moraes
             Credit Suisse            Phone: (55 11) 3841-6302
                                      E-mail: marcel.moraes@credit-suisse.com


                                      Juliana Rozenbaum – Marcio Osako
                                      Phone: (55 11) 3073-3035 / (55 11) 3073-3040
             Itaú BBA
                                      E-mail: juliana.rozenbaum@itausecurities.com
                                      E-mail: marcio.osako@itausecurities.com


                                      Iago Whately
             Banco Fator              Phone: (55 11) 3049-9480
                                      E-mail: iwhately@bancofator.com.br


                                      Guilherme Assis
             Raymond James            Phone: (55 11) 3513-8706
                                      E-mail: guilherme.assis@raymondjames.com


                                      João Carlos dos Santos
             BTG Pactual              Phone: (55 11) 3383-2384
                                      E-mail: joaocarlos.santos@btgpactual.com



                                                                                          17
IR Contacts

              Max Fischer
        CFO and IR Director

                Beatriz Diez
                 IR Manager

Telephone: 55 (21) 4009 0276
  E-mail: ri@profarma.com.br
      www.profarma.com.br/ir

More Related Content

What's hot (17)

Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11
 
Profarma 4 q11
Profarma 4 q11Profarma 4 q11
Profarma 4 q11
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Eng
 
2Q10 final
2Q10 final2Q10 final
2Q10 final
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 final
 
FY 2011 IFRS Results
FY 2011 IFRS ResultsFY 2011 IFRS Results
FY 2011 IFRS Results
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07
 
Presentation 2Q12
Presentation 2Q12Presentation 2Q12
Presentation 2Q12
 
Apresentação 3 q11 e 9m11 eng
Apresentação 3 q11 e 9m11 engApresentação 3 q11 e 9m11 eng
Apresentação 3 q11 e 9m11 eng
 
4 q08
4 q084 q08
4 q08
 
3 q10 final
3 q10 final3 q10 final
3 q10 final
 
Presentation 3Q12
Presentation 3Q12Presentation 3Q12
Presentation 3Q12
 
Apimec – 4 q07 results
Apimec – 4 q07 resultsApimec – 4 q07 results
Apimec – 4 q07 results
 
Investors meeting 1 q08 results
Investors meeting   1 q08 resultsInvestors meeting   1 q08 results
Investors meeting 1 q08 results
 
Presentation 1Q12 | Locamerica
Presentation 1Q12 | LocamericaPresentation 1Q12 | Locamerica
Presentation 1Q12 | Locamerica
 
FY 2009 IFRS results
FY 2009 IFRS resultsFY 2009 IFRS results
FY 2009 IFRS results
 

Similar to Profarma 3Q10

Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11
Profarma
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
Profarma
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
Profarma
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results
Embraer RI
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
Profarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 EngProfarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 Eng
profarma1
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 Presentation
Profarma
 
Earnings Release 3 Q07
Earnings Release 3 Q07Earnings Release 3 Q07
Earnings Release 3 Q07
Profarma
 
Apresentação 1 t11 eng
Apresentação 1 t11 engApresentação 1 t11 eng
Apresentação 1 t11 eng
Localiza
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12
Profarma
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
Profarma
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
Profarma
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
Profarma
 
2009 - First Quarter Results 2009 Usgaap
2009 - First Quarter Results 2009   Usgaap2009 - First Quarter Results 2009   Usgaap
2009 - First Quarter Results 2009 Usgaap
Embraer RI
 
First Quarter Results 2009 - USGAAP
First Quarter Results 2009 - USGAAPFirst Quarter Results 2009 - USGAAP
First Quarter Results 2009 - USGAAP
Embraer RI
 
04 30 2009 I First Quarter Results 2009 Usgaap
04 30 2009 I First Quarter Results 2009   Usgaap04 30 2009 I First Quarter Results 2009   Usgaap
04 30 2009 I First Quarter Results 2009 Usgaap
Embraer RI
 
100804 apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
100804   apresentação de resultados 2 t10-inglês_sem script [modo de compatib...100804   apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
100804 apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
Multiplus
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 Presentation
Profarma
 

Similar to Profarma 3Q10 (20)

Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Profarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 EngProfarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 Eng
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 Presentation
 
Earnings Release 3 Q07
Earnings Release 3 Q07Earnings Release 3 Q07
Earnings Release 3 Q07
 
Apresentação 1 t11 eng
Apresentação 1 t11 engApresentação 1 t11 eng
Apresentação 1 t11 eng
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
 
2009 - First Quarter Results 2009 Usgaap
2009 - First Quarter Results 2009   Usgaap2009 - First Quarter Results 2009   Usgaap
2009 - First Quarter Results 2009 Usgaap
 
First Quarter Results 2009 - USGAAP
First Quarter Results 2009 - USGAAPFirst Quarter Results 2009 - USGAAP
First Quarter Results 2009 - USGAAP
 
04 30 2009 I First Quarter Results 2009 Usgaap
04 30 2009 I First Quarter Results 2009   Usgaap04 30 2009 I First Quarter Results 2009   Usgaap
04 30 2009 I First Quarter Results 2009 Usgaap
 
100804 apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
100804   apresentação de resultados 2 t10-inglês_sem script [modo de compatib...100804   apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
100804 apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 Presentation
 

More from Profarma

Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016
Profarma
 

More from Profarma (20)

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 Presentation
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings release
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain Acquisition
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16
 
Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vf
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejo
 
1 q16
1 q161 q16
1 q16
 
4 t15
4 t154 t15
4 t15
 

Profarma 3Q10

  • 1. 3Q10 Earnings Release November, 09th, 2010.
  • 2. 3Q10 Earnings Release Highlights For The Period • A growth of 11.8% in the consolidated gross revenues quarter-over-quarter, totaling R$ 809.8 million, highlighting the health and beauty category, in which a sharp growth of 34.3% was recorded; • The operating cash flow was positive for the second consecutive quarter and amounted to R$ 62.1 million in 3Q10, or 9.1% of the net operating revenue; • Deep drop of 17.4 days in the Company's cash cycle, which stood at 48.8 days, the shortest since 2006. This decrease derived in a fall of about R$ 106.1 million in working capital; • Net debt fell by 42.9% (R$ 57.4 million) quarter-over-quarter. Thus, the Company's net debt / EBITDA ratio dropped from 1.4x (June 2010) to 0.8x; • A 9.6% drop over 2Q10 in operating expenses (administrative, selling and logistics), which resulted in 7.1% of net revenues, the latter figure being the second best result for the Company in two years; • An EPM (errors per million units delivered) reduction of 23.1% from 121.0 in 2Q10 to 93.0 in 3Q10. 2
  • 3. 3Q10 Earnings Release Gross Revenues Evolution (R$ million) 808.2 809.8 724.7 3Q09 2Q10 3Q10 3
  • 4. 3Q10 Earnings Release Gross Revenues Breakdown (R$ Million) 3Q10 3Q09 Chg. % 2Q10 Chg. % Branded 537.8 548.5 -1.9% 477.5 12.6% Generic 56.2 43.7 28.6% 50.3 11.8% OTC 153.7 157.5 -2.4% 143.8 6.9% Health and Beauty Products 38.6 27.1 42.7% 28.8 34.3% Hospitals and Vaccines 23.5 31.5 -25.4% 24.3 -3.3% Total 809.8 808.2 0.2% 724.7 11.8% 4
  • 5. 3Q10 Earnings Release Market Share Evolution (%) 11.7 11.5 10.9* 11.0* 10.2* 9.6 9.6 9.5* 2005 2006 2007 2008 2009 3Q09 2Q10 3Q10 *Excluding the similar’s effect Source: IMS 5
  • 6. 3Q10 Earnings Release Gross Profit and Revenues from Services to Suppliers (R$ million and as % Net Revenues) 12.3% 11.1% 10.2% 10.3 25.1 26.8 65.8 49.7 43.3 3Q09 2Q10 3Q10 Gross Profit Revenues from Services to Suppliers Gross Profit Margin (%) 6
  • 7. 3Q10 Earnings Release Operating Expenses (R$ million and as % Net Revenues ) 8.9% 6.9% 7.1% 53.8 48.6 47.4 3Q09 2Q10 3Q10 7
  • 8. 3Q10 Earnings Release Net Financial Expenses (R$ million and as % Net Revenues) 1.9% 0.7% 0.8% 11.8 5.4 5.1 3Q09 2Q10 3Q10 8
  • 9. 3Q10 Earnings Release Net Profit (R$ million and as % Net Revenues) 1.9% 1.9% 0.7% 13.1 11.4 4.7 3Q09 2Q10 3Q10 9
  • 10. 3Q10 Earnings Release Ebitda and Ebitda Margin (R$ million and as % Net Revenues) 4.1% 3.6% 3.1% 27.7 21.8 21.5 3Q09 2Q10 3Q10 10
  • 11. 3Q10 Earnings Release CASH FLOW (R$ Million) 3Q10 3Q09 Chg. % 2Q10 Chg. % Cash Flow Generated / (Used) in Operating Activities 62.1 36.5 70.2% 46.8 32.8% Internal Cash Generation 9.5 24.1 -60.7% 17.6 -46.1% Operating Assets Variation 52.7 12.4 325.9% 29.2 80.3% Trade Accounts Receivable (50.8) (1.9) -2561.4% 28.3 - Inventories - - (10.2) 26.7 92.4 Suppliers 120.7 (3.9) - (105.2) - Other Items (7.1) (8.5) 16.4% 13.7 - Cash Flow (Used) in Investing Activities (1.5) (2.2) 31.9% (1.9) 20.1% Cash Flow Generated / (Used) by Financing Activities (43.8) (17.1) -155.9% (53.7) 18.5% Net Increase / (Decrease) in Cash 16.9 17.2 -2.0% (8.8) - 11
  • 12. 3Q10 Earnings Release 3Q06 4Q06 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 1Q10 2Q10 3Q10 Cash Cycle – Days * 49.3 53.4 62.5 69.6 67.8 64.3 68.8 67.2 61.8 65.8 67.9 58.7 51.6 52.7 64.9 66.3 48.8 Accounts Receivable (1) 45.2 50.0 54.6 53.1 50.9 51.7 50.7 49.2 47.0 45.9 42.4 40.5 38.4 41.1 43.4 42.2 43.3 Inventories (2) 33.1 44.7 43.4 47.2 41.3 48.6 47.9 45.7 42.5 49.9 61.6 52.4 43.7 53.9 59.9 48.8 43.9 Accounts Payable (3) 29.0 41.3 35.6 30.7 24.5 36.0 29.8 27.7 27.7 29.9 36.1 34.3 30.5 42.3 38.4 24.8 38.4 * Average (1) Average of Gross Revenues in the Quarter (2) Average of COGS in the Quarter (3) Average of COGS in the Quarter 12
  • 13. 3Q10 Earnings Release Indebtedness: Net Debt and Net Debt / Ebitda* (R$ million) 1.4x 0.9x 0.8x 132.5 95.0 75.1 3Q09 2Q10 3Q10 * Ebitda = Accumulated last 12 months 13
  • 14. 3Q10 Earnings Release Capex (R$ million and as % Net Revenues) 0.3% 0.3% 0.2% 2.2 1.9 1.5 3Q09 2Q10 3Q10 14
  • 15. 3Q10 Earnings Release Operating Indicators Service Level Logistics E.P.M. (units served / units requested) (Errors per Million) 94.1% 120.0 121.0 90.4% 93.0 89.6% 3Q09 2Q10 3Q10 3Q09 2Q10 3Q10 15
  • 16. 3Q10 Earnings Release Profarma vs Ibovespa - % 1 year 150 125 113 100 103 75 50 30-sep-09 30-nov-09 30-jan-10 30-mar-10 30-may-10 30-jul-10 30-sep-10 Ibovespa Profarma 16
  • 17. 3Q10 Earnings Release Analyst Coverage Firm Analyst Javier Martinez de Olcoz Cerdan – Clarissa Berman Phone: (1 212) 761-4542 / (55 11) 3048-6214 Morgan Stanley E-mail: javier.martinez.olcoz@morganstanley.com E-mail: clarissa.berman@morganstanley.com Alexandre Pizano Merrill Lynch Phone: (55 11) 2188-4024 E-mail: alexandre.pizano@baml.com Marcel Moraes Credit Suisse Phone: (55 11) 3841-6302 E-mail: marcel.moraes@credit-suisse.com Juliana Rozenbaum – Marcio Osako Phone: (55 11) 3073-3035 / (55 11) 3073-3040 Itaú BBA E-mail: juliana.rozenbaum@itausecurities.com E-mail: marcio.osako@itausecurities.com Iago Whately Banco Fator Phone: (55 11) 3049-9480 E-mail: iwhately@bancofator.com.br Guilherme Assis Raymond James Phone: (55 11) 3513-8706 E-mail: guilherme.assis@raymondjames.com João Carlos dos Santos BTG Pactual Phone: (55 11) 3383-2384 E-mail: joaocarlos.santos@btgpactual.com 17
  • 18. IR Contacts Max Fischer CFO and IR Director Beatriz Diez IR Manager Telephone: 55 (21) 4009 0276 E-mail: ri@profarma.com.br www.profarma.com.br/ir